Afamelanotide official-source update · version 1
This page preserves this version’s findings and source pins. Open the current profile →
Official-source update
Reviewed 2026-09-19 · Preserved version 1
The variegate-porphyria study was very small and uncontrolled
NCT05854784 records six participants in an open-label, single-group phase 2 study. This is a different condition and design from the randomized erythropoietic-protoporphyria program. NCT05854784 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
An observed rating change is not a controlled treatment effect
The variegate-porphyria record reports a median clinical global-impression change score of 2.5 at day 168 among six participants. Without a control group and blinded assessment, this finding alone cannot establish how much change afamelanotide caused. NCT05854784 ↗
The newer EPP record focuses on pharmacokinetics
NCT06388642 records 28 participants with erythropoietic protoporphyria in a completed single-group study. Its primary outcomes measure peak plasma concentration and exposure over seven days, rather than a randomized comparison of clinical efficacy. NCT06388642 ↗
Age eligibility is not proof of an age-specific result
The pharmacokinetic study permits ages 12–70 but posts aggregate results for 28 participants. Those aggregate values do not establish a separate adolescent efficacy effect or show that every eligible age was represented. NCT06388642 ↗
What remains to be checked
- Appraise the six-person variegate-porphyria report and reconcile outcome definitions and safety details.
- Review age-specific pharmacokinetic data and later EPP evidence without inferring pediatric efficacy from eligibility alone.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP) ↗
Source dated 2025-04-27; retrieved 2026-09-19.
- protocolSection.identificationModule, designModule and armsInterventionsModule
- protocolSection.eligibilityModule and armsInterventionsModule
- resultsSection.outcomeMeasuresModule
SHA-256:
5b7d65ab39da370ec4a017425e4c2cc62ae6c0fc48b0c5d2e636da0523ff6099Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients ↗
Source dated 2026-07-27; retrieved 2026-09-19.
- protocolSection.identificationModule, designModule and armsInterventionsModule
- protocolSection.eligibilityModule and armsInterventionsModule
- resultsSection.outcomeMeasuresModule
SHA-256:
3ef889a13159fc222504d3f99265fdd145895cb9d7771e24dd51691165c52ffe